Traws Pharma, Inc. (Nasdaq: TRAW), a clinical-stage biopharmaceutical company based in Newtown, Pennsylvania, announced a private placement financing of up to USD 60 million on April 15, 2026, structured to fund the advancement of its lead influenza asset through a human challenge trial in the United Kingdom. The immediate capital need centers on completing that Challenge Trial for tivoxavir marboxil, with the financing architecture designed to release additional tranches contingent on regulatory and clinical milestones rather than providing the full sum upfront.
The PIPE financing delivers approximately USD 10.0 million in upfront gross proceeds at closing, priced at USD 1.6730 per share of common stock, with pre-funded warrants available in lieu of shares. The transaction also includes three warrant series that together represent up to USD 50.0 million in additional potential proceeds. The Series A warrant carries potential gross proceeds of approximately USD 10.0 million and becomes exercisable upon receipt of approval from the UK Medicines and Healthcare products Regulatory Agency to conduct the human challenge trial. The Series B warrant, also carrying approximately USD 10.0 million in potential proceeds, is exercisable following both shareholder approval and the announcement of challenge trial data. The Series C warrant provides potential proceeds of approximately USD 30.0 million over a three-year term, exercisable following shareholder approval. All warrants carry an exercise price equal to the deal price of USD 1.6730, as the transaction was priced at-the-market under Nasdaq rules. The financing was led by Sirenia Capital Management LP, with additional participation from new and existing institutional and accredited investors whose individual identities were not disclosed. No insider participation was referenced in the press release. Cantor Fitzgerald & Co. served as lead placement agent, with Citizens JMP Securities, LLC and Tungsten Advisors LLC, acting through its broker-dealer Finalis Securities LLC, serving as co-placement agents. Closing occurred on April 15, 2026, with funding expected April 16, 2026, subject to customary closing conditions.
Company overview and pipeline
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule antiviral agents targeting respiratory viral diseases, including seasonal influenza, H5N1 avian influenza, and COVID-19. The company was formed in April 2024 through a merger between Onconova Therapeutics and Trawsfynydd Therapeutics, with the combined entity commencing trading on Nasdaq under the ticker TRAW. That merger was accompanied by a USD 14.0 million PIPE financing from OrbiMed and Torrey Pines Investment.
The lead asset, tivoxavir marboxil, is in development as a once-monthly oral prophylactic agent for influenza prevention, with additional potential as a single-dose treatment for seasonal influenza or H5N1. The compound targets the influenza cap-dependent endonuclease. The proceeds from the current financing are directed toward completing the UK Challenge Trial for tivoxavir marboxil, with the Series A warrant milestone contingent on MHRA approval to proceed with that study. The company's IND filing with the FDA for tivoxavir marboxil is subject to a current FDA clinical hold, a risk factor disclosed in the press release's forward-looking statements section.